Literature DB >> 24598047

Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors.

Qin Li1, Yun Zhang2, Adel K El-Naggar3, Shunbin Xiong2, Peirong Yang2, James G Jackson2, Gilda Chau2, Guillermina Lozano4.   

Abstract

UNLABELLED: The p53 (TP53) tumor suppressor is the most frequently mutated gene in human cancers. Restoring expression of wild-type p53 has led to tumor growth suppression in a variety of tumor models that are p53 deficient. Other mechanisms, for example, upregulation of Mdm2, exist in tumors to inactivate the p53 pathway. Mdm2, an E3 ubiquitin ligase that targets p53 for proteasomal degradation, is present at high levels in many tumors with wild-type p53. In this study, the effects of restoring p53 activity were probed in Mdm2-overexpressing tumors genetically using animal models. Here, it was demonstrated that elevated levels of Mdm2 and decreased levels of p53 act additively to dampen p53 activity in DNA damage response and tumor development. Our data further indicate that restoration of wild-type p53 expression in Mdm2-overexpressing angiosarcomas results in tumor stasis and regression in some cases. Finally, it was determined that restored p53 suppressed cell proliferation but did not elicit apoptosis in the Mdm2-overexpressing angiosarcomas. IMPLICATIONS: Restoration of wild-type p53 expression in Mdm2-overexpressing tumors suppresses tumor growth, which represents a potential clinical strategy to treat tumors with high levels of Mdm2. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24598047      PMCID: PMC4058386          DOI: 10.1158/1541-7786.MCR-14-0089

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  37 in total

1.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

2.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.

Authors:  Wen Xue; Lars Zender; Cornelius Miething; Ross A Dickins; Eva Hernando; Valery Krizhanovsky; Carlos Cordon-Cardo; Scott W Lowe
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

Review 3.  Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4.

Authors:  J-C Marine; S Francoz; M Maetens; G Wahl; F Toledo; G Lozano
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

4.  Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.

Authors:  S N Jones; A R Hancock; H Vogel; L A Donehower; A Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells.

Authors:  Hafid Alazzouzi; Gianpaolo Suriano; Angel Guerra; Alberto Plaja; Eloi Espín; Manel Armengol; Pia Alhopuro; Sergia Velho; Yasuhisa Shinomura; Juan José González-Aguilera; Hiroyuki Yamamoto; Lauri A Aaltonen; Víctor Moreno; Gabriel Capellà; Miguel Angel Peinado; Raquel Seruca; Diego Arango; Simó Schwartz
Journal:  J Med Genet       Date:  2006-07-06       Impact factor: 6.318

6.  Modeling the therapeutic efficacy of p53 restoration in tumors.

Authors:  Carla P Martins; Lamorna Brown-Swigart; Gerard I Evan
Journal:  Cell       Date:  2006-12-21       Impact factor: 41.582

7.  Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

Authors:  Gene A Lang; Tomoo Iwakuma; Young-Ah Suh; Geng Liu; V Ashutosh Rao; John M Parant; Yasmine A Valentin-Vega; Tamara Terzian; Lisa C Caldwell; Louise C Strong; Adel K El-Naggar; Guillermina Lozano
Journal:  Cell       Date:  2004-12-17       Impact factor: 41.582

8.  A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.

Authors:  M Jablkowski; A Bocian; J Bialkowska; J Bartkowiak
Journal:  J Exp Clin Cancer Res       Date:  2005-03

9.  Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse.

Authors:  Shigemi Hayashi; Andrew P McMahon
Journal:  Dev Biol       Date:  2002-04-15       Impact factor: 3.582

Review 10.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.

Authors:  Franck Toledo; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2006-12       Impact factor: 60.716

View more
  17 in total

1.  Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.

Authors:  Alexia M Carrillo; Mellissa Hicks; Dineo Khabele; Christine M Eischen
Journal:  Mol Cancer Res       Date:  2015-05-11       Impact factor: 5.852

2.  Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination.

Authors:  Rebecca A Frum; Ian M Love; Priyadarshan K Damle; Nitai D Mukhopadhyay; Swati Palit Deb; Sumitra Deb; Steven R Grossman
Journal:  Mol Cancer Res       Date:  2016-03-10       Impact factor: 5.852

Review 3.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

Review 4.  Limiting the power of p53 through the ubiquitin proteasome pathway.

Authors:  Vinod Pant; Guillermina Lozano
Journal:  Genes Dev       Date:  2014-08-15       Impact factor: 11.361

5.  Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.

Authors:  W Wu; C Xu; X Ling; C Fan; B P Buckley; M V Chernov; L Ellis; F Li; I G Muñoz; X Wang
Journal:  Cell Death Dis       Date:  2015-12-31       Impact factor: 8.469

Review 6.  Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.

Authors:  Ana B Herrero; Elizabeta A Rojas; Irena Misiewicz-Krzeminska; Patryk Krzeminski; Norma C Gutiérrez
Journal:  Int J Mol Sci       Date:  2016-11-30       Impact factor: 5.923

Review 7.  Mouse modelling of the MDM2/MDMX-p53 signalling axis.

Authors:  Nicole R Tackmann; Yanping Zhang
Journal:  J Mol Cell Biol       Date:  2017-02-01       Impact factor: 6.216

8.  MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.

Authors:  Giulia Pasello; Loredana Urso; Manlio Mencoboni; Federica Grosso; Giovanni Luca Ceresoli; Francesca Lunardi; Stefania Edith Vuljan; Roberta Bertorelle; Valeria Sacchetto; Vincenzo Ciminale; Federico Rea; Adolfo Favaretto; PierFranco Conte; Fiorella Calabrese
Journal:  Oncotarget       Date:  2015-12-08

9.  Interference with mutagenic aflatoxin B1-induced checkpoints through antagonistic action of ochratoxin A in intestinal cancer cells: a molecular explanation on potential risk of crosstalk between carcinogens.

Authors:  Juil Kim; Seong-Hwan Park; Kee Hun Do; Dongwook Kim; Yuseok Moon
Journal:  Oncotarget       Date:  2016-06-28

10.  Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling.

Authors:  Surendra Sharma; Karl Munger
Journal:  mBio       Date:  2020-06-16       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.